Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy and Itonis Pharmaceuticals to Use Its Exclusive Manufacturer for Emesy
03 Maio 2013 - 10:55AM
Itonis, Inc. (OTC:ITNS) and Charles Hensley, Ph.D., the inventor of
the Zicam® Cold Remedy, and founding member of Itonis
Pharmaceuticals, are pleased to announce that the Company's
exclusive manufacturer (Oasis Health Products, Inc.) will produce
the Company's anti-nausea swab and its oral spray products under
the Emesyl™ brand.
The Company expects to commence the production process with
Oasis Health Products for Emesyl™ in both the swab and oral spray
forms.
Dr. Hensley said, "We are excited that we are working with Oasis
to produce the first of our Emesyl™ anti-nausea products. We look
forward to making Emesyl™ available to the general public to treat
nausea ailments."
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is
headed by Charles Hensley, Ph.D. This division's mission is to
create and market over-the-counter and prescription homeopathic
products that better people's lives. Dr. Hensley is a pioneer in
the development and marketing of safe and effective therapeutic
nutraceutical and homeopathic preparations. He was a founder of the
company that launched the Zicam® Cold Remedy, making the product a
household name and forever changing the marketing and product
placement paradigm for homeopathic drugs in the United
States. Dr. Hensley and his team plan to use the same
methodologies to revolutionize the treatment of several other
common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5,
2005 under the name of Kenshou, Inc., which later changed to
Itonis, Inc. on December 2, 2005. For more information, please
visit www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
CONTACT: Michael Biddick
mike@itonisholdings.com
(949) 529-1588
Itonis (PK) (USOTC:ITNS)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Itonis (PK) (USOTC:ITNS)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025